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ABSTRACT
Background   Remnant gastric cancer (RGC) is an un-
common form of gastric cancer. The aim of this study 
was to investigate factors influencing the prognosis of 
patients with RGC. 
Methods   A total of 49 patients diagnosed with RGC 
and 214 patients with primary upper third gastric cancer 
(PUGC) at our institution between January 1990 and 
December 2014 were included. The clinicopathological 
characteristics, prognosis, and factors influencing prog-
nosis were compared.
Results   The body mass index (BMI) of RGC was 
significantly lower than that for PUGC (P < 0.0001). 
Multivariate analysis revealed that BMI and the depth 
of tumor invasion were independent prognostic factors 
in RGC. ROC analysis indicated that an optimal cut-off 
value for BMI was 20.6. Based on this value, patients 
were divided into two groups: BMIHigh (≥ 20.6) and 
BMILow (< 20.6). The 5-year survival rates of patients 
with BMIHigh early gastric cancer, BMIHigh advanced 
gastric cancer, BMILow early gastric cancer, and BMILow 
advanced gastric cancer were 90%, 83.3%, 64.3% and 
33.8%, respectively, and the difference was statistically 
significant (P = 0.00023). 
Conclusion   Our retrospective study indicated a poor 
prognosis of RGC compared with PUGC, and that BMI 
could predict the prognosis of RGC. The prognosis of 
patients with BMILow advanced RGC was extremely 
poor.
Key words   body mass index; gastric cancer; prognosis; 
remnant gastric cancer
Gastric cancer is one of the most common malignancies 
and death from gastric cancer ranks second among all 
cancer deaths worldwide.1 Remnant gastric cancer (RGC) 
is a less prevalent form of the disease, and the incidence 
of RGC has been reported as 1–7% of all gastric cancer 
cases.2-4 The most frequently used definition of RGC is 
cancer in the remnant stomach after surgery for benign 
disease or cancer after surgery for gastric cancer found 
at least 5 years after the primary surgery. Surgery, in-
cluding gastrectomy, has been the standard treatment 
for peptic ulcer disease in previous decades.5 Recent 
advances in peptic ulcer therapy, including specific 
treatment for Helicobacter pylori infection, have de-
creased the prevalence of affected individuals for whom 
gastrectomy is indicated. Therefore, it is likely that the 
incidence of RGC following gastrectomy for benign 
disease will decrease in the future. However, the inci-
dence of RGC following gastrectomy for gastric cancer 
is increasing as a result of improved survival and early 
detection by mass screening, especially in several Asian 
countries.6 Therefore, rates of RGC following gastric 
cancer surgery have been increasing overall.7, 8 
 RGC is often diagnosed at an advanced stage, with 
higher rates of invasion of adjacent organs and lymph 
node metastases,9, 10 low rate of curative resection and, 
consequently, a poor prognosis.10, 11 It has been also re-
ported that the prognosis for RGC is significantly worse 
than that for primary upper third gastric cancer (PUGC) 
that originates in the almost same lesion as RGC, when 
compared at the same stage, indicating the possibility 
that the characteristics of RGC might be different from 
those of primary gastric cancer. 
 Determining the postoperative prognosis in RGC 
patients is extremely important. Many studies have in-
dicated that depth of invasion and presence or absence 
of lymph node metastasis are the most important prog-
nostic factors in gastric cancer.12, 13 However, the factors 
influencing the poor prognosis of patients with RGC 
remain unclear. The purpose of this study was to investi-
gate the clinicopathological characteristics and outcomes 
127
Useful predictor of BMI in RGC
of surgery for RGC following distal gastrectomy. In par-
ticular, we examined the factors related to the prognosis 
of patients with RGC. 
MATERIALS AND METHODS
Patients
This study was based on a retrospective analysis of 49 
RGC patients following distal gastrectomy who under-
went curative gastrectomy at our institution between 
January 1990 and December 2014. During the same 
period, 214 patients were pathologically diagnosed with 
adenocarcinoma confined to the upper third of the stom-
ach and were also included in the current study. The 
clinicopathological findings were determined according 
to the Japanese Classification of Gastric Carcinoma.14 
Patients were periodically checked for early recurrence 
by diagnostic imaging (chest X-ray, double-contrast 
barium meal study, upper gastrointestinal fiberscopy, 
ultrasonography, and computed tomography). Causes 
of death and patterns of recurrence were determined by 
reviewing medical records, including laboratory data, 
ultrasonography, computed tomography, scintigrams, 
peritoneal punctures, and laparotomies, or by direct in-
quiry to family members. In some cases, postmortems 
were undertaken to determine the cause of death. Insti-
tutional review board approval was obtained (1607A064), 
and informed consent requirements were waived for this 
study.
Statistical analysis
The Mann–Whitney U test and chi-square test were 
employed to evaluate differences in continuous and cat-
egorical variables, respectively. The Youden index was 
calculated using receiver operating characteristic (ROC) 
analysis to determine an optimal cutoff value for body 
mass index (BMI) for survival analysis. Survival curves 
were calculated using the Kaplan–Meier method. Differ-
ences between survival curves were examined with the 
log-rank test. Survival data shown in the current study 
were for overall survival (OS). We used multivariate 
analysis of factors considered prognostic of OS, with 
Cox’s proportional hazards model. SPSS Statistics (ver. 
24.0 software, IBM) was used for all statistical anal-
yses, with P < 0.05 considered statistically significant 
(2-tailed).
RESULTS
Clinicopathological features of RGC and PUGC
The clinicopathological characteristics of both RGC and 
PUGC are shown in Table 1. Patients with RGC were 
significantly older than those with PUGC (P = 0.002). 6 
patients with RGC were older than 80 years old (12.2%) 
and one patient was over 85 years old. The frequency of 
male gender was significantly greater in RGC patients 
than in PUGC patients (P = 0.041). Furthermore, BMI 
was significantly lower in RGC patients than in PUGC 
patients (P < 0.0001). However, no significant differenc-
es were observed in tumor size, depth of tumor invasion, 
lymph node metastasis, blood vessel invasion, lymphatic 
vessel invasion, and state of disease between RGC and 
PUGC. 
Table1. The clinicopathological features of RGC and 
PUGC
RGC (n = 49) PUGC (n = 214) P value
Age (years) 72.4 ± 6.8 66.2 ± 12.2 0.002
Gender 0.041
Male 43 (87.8%) 158 (73.8%)
Female 6 (12.2%) 56 (26.2%)
Tumor size (mm) 42.9 ± 26.1 36.3 ± 23.1 0.14
BMI 20.3 ± 2.6 22.6 ± 3.1 < 0.0001
Histology* 0.53
Differentiated 25 (51.0%) 121 (56.5%)
Undifferenciated 24 (49.0%) 93 (43.5%)
Depth of invasion† 0.27
T1 23 (46.9%) 126 (58.9%)
T2 6 (12.2%) 31 (14.5%)
T3 9 (18.4%) 27 (12.6%)
T4 11 (22.5%) 30 (14.0%)
Lymph node metastasis 0.44
Present 13 (26.5%) 57 6.6%)
Absent 26 (73.5%) 157 (73.4%)
Lymphatic invasion 0.53
Present 28 (57.1%) 111 (51.9%)
Absent 21 (42.9%) 103 (48.1%)
Blood vessel invasion 0.20
Present 27 (55.1%) 94 (43.9%)
Absent 22 (44.9%) 120 (56.1%)
Stage of disease 0.41
I 26 (53.1%) 139 (65.0%)
II 13 (26.5%) 39 (18.2%)
III 10 (20.4%) 35 (16.4%)
IV 0 (0%) 1 (0.4%)
*Differentiated, papillary or tubular adenocarcinoma; undiffer-
entiated, poorly differentiated, mucinous adenocarcinoma, and 
signet-ring cell carcinoma
†T1, tumor has invaded lamina propria or submucosa; T2, tumor 
has invaded the muscularis propria; T3, tumor has invaded the 
subserosa; T4, tumor invasion is contiguous to or exposed beyond 
the serosa or tumor invades adjacent structures. 
BMI, body mass index; PUGC, primary upper third gastric can-
cer; RGC, remnant gastric cancer.
Prognosis of patients with RGC or PUGC
The 5-year survival rates of patients with RGC and 
PUGC were 57.9% and 76.2%, respectively, and the 
difference was statistically significant (P = 0.0094, Fig. 
1). In detail, no significant difference in prognosis was 
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Fig. 1. Survival curves following gastrectomy of RGC and PUGC. 
The 5-year survival rates of RGC and PUGC were 57.9% and 
76.2%, respectively, and the difference was statistically signifi cant 
(P = 0.0094). PUGC, primary upper third gastric cancer; RGC, 
remnant gastric cancer. 
Fig. 2. (A) Survival curves of patients with either early RGC or 
early PUGC. (B) Survival curves of patients with either node-neg-
ative advanced RGC or node-negative advanced RGC. (C) Surviv-
al curves of patients with either node-positive advanced RGC or 
node-positive advanced RGC. PUGC, primary upper  third gastric 
cancer; RGC, remnant gastric cancer. 
observed between early RGC patients and early PUGC 
patients (P = 0.71, Fig. 2a). However, the prognosis of 
patients with node-negative advanced RGC was signifi -
cantly worse than that of patients with node-negative 
advanced PUGC (P = 0.0036, Fig. 2b). There was no 
significant difference in prognosis between node-posi-
tive RGC patients and node-positive PUGC patients (P = 
0.69, Fig. 2c). Since a signifi cant difference in prognosis 
was observed between node-negative advanced RGC 
and node-negative advanced PUGC, the sites of recur-
rence of either RGC or PUGC were determined in those 
patients. Peritoneal, hematogenous, and lymph node 
recurrence were observed in 3 (20%), 3 (20%), and 2 
patients (13.3%) with node-negative advanced RGC and 
1 (2.3%), 2 (4.7%), and no patients (0%) in node-negative 
advanced PUGC. Peritoneal recurrence was observed 
signifi cantly more in RGC than in PUGC patients (P = 
0.049), although there was no significant difference in 
hematogenous (P = 0.1) and lymph node recurrence (P = 
0.064) between RGC and PUGC.
Factors related to prognosis in RGC and PUGC
We next examined factors related to prognosis in both 
RGC and PUGC. Univariate analysis revealed that BMI, 
tumor size, and depth of tumor invasion were signifi cant 
prognostic factors in RGC, and that age, tumor size, 
depth of tumor invasion, lymph node metastasis, lym-
phatic invasion, and venous invasion were significant 
prognostic factors in PUGC (Tables 2 and 3). Further-
more, multivariate analysis revealed that BMI and depth 
of tumor invasion were independent prognostic factors in 
RGC (Table 2). However, age, depth of tumor invasion, 
and lymph node metastasis were found to be indepen-
dent prognostic factors in PUGC (Table 3).
 Because BMI and depth of tumor invasion were in-
dependent prognostic indicators, we determined whether 
an accurate prognosis of RGC could be predicted using 
BMI and depth of tumor invasion. ROC analysis indicat-
ed that an optimal cut-off value for BMI was 20.6 (AUC 
0.746, P = 0.0031) (Fig. 3). Based on this value, patients 
were divided into two groups as follows: BMIHigh (≥ 
20.6) and BMILow (< 20.6). The 5-year overall survival 
129
Useful predictor of BMI in RGC
rates of patients with BMIHigh early gastric cancer, BMI-
High advanced gastric cancer, BMILow early gastric cancer, 
and BMILow advanced gastric cancer were 90%, 83.3%, 
64.3% and 33.8%, respectively, and the difference was 
statistically signifi cant (Fig. 4a). The 5-year disease spe-
cifi c survival rates of patients with BMIHigh early gastric 
cancer, BMIHigh advanced gastric cancer, BMILow early 
gastric cancer, and BMILow advanced gastric cancer were 
Matsunaga et.al Figure 3
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Fig. 3. ROC analysis indicated that an optimal cut-off value for 
BMI was 20.6. The BMI had good diagnostic accuracy (AUC 
0.746, sensitivity 82.6%, specifi city 61.0%, P = 0.0031). The arrow 
shows the optimal cutoff point. ROC, receiver operating charac-
teristic.
Table 2. Univariate and multivariate analyses of factors prognostic of overall survival in patients with RGC
Univariate analysis Mutivariate analysis
HR 95% CI P value HR 95% CI P value
Age* 0.997 0.936−1.063 0.936
Gender (Male vs Female) 0.776 0.180−3.345 0.733
BMI* 0.723 0.579−0.902 0.00417 0.731 0.563−0.949 0.018
Histology  (Differentiated vs Undifferentiated)† 0.516 0.216−1.232 0.136
Tumor size* 1.014 1.003−1.025 0.01 0.994 0.973−1.016 0.512
Depth of tumor invasion (T1−T4) ‡ 1.837 1.289−2.616 0.000755 1.989 1.122−3.527 0.004
Lymph node metastasis (N0−N3)§ 1.759 0.735−4.208 0.205
Lymphatic invasion (Ly0−Ly3)|| 1.086 0.698−1.688 0.715
Venous invasion (V0−V3)¶ 1.438 1.038−1.992 0.029 0.994 0.598−1.509 0.6
*Continuous variable
†Histology: Differentiated, papillary or tubular adenocarcinoma; undifferentiated, poorly differentiated or mucinous adenocarcinoma, 
or signet ring cell carcinoma
‡T1, tumor has invaded lamina propria or submucosa; T2, tumor has invaded the muscularis propria; T3, tumor has invaded the subse-
rosa; T4, tumor invasion is contiguous to or exposed beyond the serosa or tumor invades adjacent structures.
§N0, no regional lymph node metastases; N1, metastasis in 1−2 regional lymph nodes; N2, metastasis in 3−6 regional lymph nodes; 
N3,metastasis in 7 or more regional lymph nodes.
||Lymphatic vessel invasion: ly0-ly3, grade of lymphatic invasion.
¶Blood vessel invasion: v0-v3, grade of venous invasion.
BMI, body mass index; CI, confi dence interval; HR, hazard ratio; RGC, remnant gastric cancer.
Table 3. Univariate and multivariate analyses of factors prognostic of overall survival in patients with PUGC
Univariate analysis Mutivariate analysis
HR 95% CI P value HR 95% CI P value
Age* 1.074 1.045−1.104 < 0.0001 1.078 1.047−1.110 0.0001
Gender (Male vs Female) 0.882 0.472−1.648 0.694
BMI* 0.986 0.913−1.065 0.72
Histology (Differentiated vs Poorly differentiated) 1.148 0.669−1.969 0.882
Tumor size* 1.013 1.004−1.023 0.00479 0.998 0.983−1.013 0.811
Depth of tumor invasion (T1−T4) 1.682 1.367−2.070 < 0.0001 1.399 1.002−1.955 0.048
Lymph node metastasis (N0−N3) 1.913 1.536−2.383 < 0.0001 1.679 1.212−2.324 0.0018
Lymphatic invasion (Ly0−Ly3) 1.517 1.226−1.878 0.00013 0.988 0.714−1.389 0.981
Venous invasion (V0−V3) 1.57 1.226−2.009 0.00034 0.977 0.711−1.341 0.885
*Continuous variable
See Table 2 for details of histology, depths of nvasion, lymph node metastasis, lymphatic invasion, and venous invasion.
BMI, body mass index; CI, confi dence interval; HR, hazard ratio; PUGC, primary upper third gastric cancer.
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Fig. 4. Survival curves of patients with RGC according to BMI and depth of invasion. (A) The 5-year overall survival rates of patients 
with RGC. (B) The 5-year disease specific survival rates of patients with RGC. BMI, body mass index; RGC, remnant gastric cancer.
90%, 83.3%, 90% and 42%, respectively, and the differ-
ence was statistically significant (Fig. 4b). Furthermore, 
recurrence was observed in 11 patients (57.9%) out of 19 
with BMILow advanced gastric cancer and 3 patients out 
of the remaining patients (10%), a difference that was 
statistically significant (P = 0.0007). Two patients with 
RGC died of other cancer and 6 patients with RGC died 
of other disease such as pneumonia or heart failure or 
myocardial infarction in RGC. 
DISCUSSION
We have demonstrated in the current study that the prog-
nosis of RGC was significantly worse than that of PUGC. 
This result is similar to that previous reports.15, 16 The poor 
prognosis of RGC may be affected by the stage distri-
bution of the patients. In the study by Tokunaga et al., 
43.1% of the RGC group comprised tumor penetration 
of serosa (SE) or tumor invasion of adjacent structure (SI) 
patients; in contrast, only 18.9% of the primary gastric 
cancer group included these patients.15 However, this 
does not seem to explain the poor prognosis observed 
in the current study because there was no significant 
difference in depth of invasion, lymph node metastasis, 
and stage of disease between RGC and PUGC patients. 
Another possibility is the molecular changes observed in 
RGC. The remnant stomach is frequently exposed to bile 
and pancreatic juice, which can induce molecular chang-
es in the gastric mucosa. In a retrospective study with 
130 patients, Leivonen et al. analyzed the cell prolifera-
tion rate in biopsy specimens from gastric remnants by 
immunohistochemical staining of Ki-67.17 The Ki-67 
labeling index of tumors was significantly higher in the 
remnant stomach group, and is known to be associated 
with bile reflux and reconstruction without bile reflux. 
Baba et al. found that p53 overexpression in tumors was 
almost twice as common in patients with gastric cancer 
of the remnant stomach than in patients that had under-
gone distal gastrectomy for benign disease.18 It has also 
been demonstrated that p53 overexpression and higher 
Ki-67 labeling index are closely related to poor progno-
sis in gastric cancer.19, 20 Therefore, the poor prognosis 
observed for RGC patients in the current study might be 
related to molecular changes. Further investigations are 
therefore required to determine the correlation between 
poor prognosis and molecular changes in RGC. 
 Anatomical alterations and intraabdominal adhe-
sions after initial surgery, as well as frequent combined 
resection of other organs, present difficulties for RGC 
surgery. Many studies have described an altered lym-
phatic pathway for RGC resulting from initial surgery. 
Furthermore, optimal lymph node dissection remains 
unclear thus far. It is likely that these surgical limitations 
are associated with poor prognosis in RGC.
 It has recently been reported that preoperative nutri-
tional status is a useful predictor of prognosis of gastric 
cancer patients. Several assessment tools can be applied 
to nutritional evaluation, such as Subjective Global 
Assessment (SGA),21 mini-nutritional assessment,22 nu-
tritional risk scoring 2002 (NRS2002),23 and Onodera’s 
prognostic nutritional index (PNI).24 Nozoe et al. have 
recently reported that PNI could predict the prognosis 
and biological aggressiveness of gastric cancer.25 With 
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regard to BMI, it has been reported that underweight 
patients with BMI < 18.5 kg/m2 and low preoperative 
albumin levels had a significantly decreased OS after 
gastrectomy for cancer,26 indicating the close correlation 
between low BMI and poor prognosis in gastric cancer 
patients. It is likely that an initial gastrectomy places 
patients in a state of malnutrition. In the current study, 
BMI was significantly lower in patients with RGC than 
in those with PUGC. Furthermore, multivariate analysis 
indicated that BMI was an independent prognostic in-
dicator, suggesting the usefulness of BMI to predict the 
prognosis of RGC patients.
 Lymph node metastasis is one of the most import-
ant prognostic factors for patients who have undergone 
curative resection for gastric cancer.27, 28 Lymph node 
metastasis was shown in the current study to be an in-
dependent prognostic indicator for PUGC. However, 
no significant difference in prognosis was observed 
between patients with lymph node metastasis and those 
without lymph node metastasis in RGC. Furthermore, 
lymph node metastasis was not an independent prognos-
tic indicator for RGC in the current study. One possible 
explanation for this is that most lymph nodes are dis-
sected in RGC patients whose initial operation was per-
formed for gastric cancer, thus lowering the significance 
of lymph node metastasis as a prognostic indicator. 
Another possible explanation is insufficient lymph node 
dissection as a result of postoperative adhesion induced 
by an initial operation, which renders subsequent lymph 
node dissection difficult. Insufficient lymph node dissec-
tion is related to stage migration and might represent one 
reason why a significant difference in prognosis between 
RGC and PUGC was observed in node-negative but not 
node-positive advanced cancer.
 The staging of gastric cancer according to the Japa-
nese Classification of Gastric Cancer system is based on 
the depth of tumor invasion, status of lymph node metas-
tasis, and presence of distant metastasis. In general, this 
staging system is used for RGC, although it is unclear 
how suitable it is for this disease subset. In this regard, 
our results indicated that factors reflecting the patient’s 
nutritional status should be included in the staging sys-
tem of RGC.
 The Japanese Gastric Cancer Treatment Guide-
line recommends adjuvant chemotherapy with S-1 for 
a year in stage II/III gastric cancer patients who have 
undergone gastrectomy with D2 lymph node dissection 
based on the results of the Adjuvant Chemotherapy Trial 
of TS-1 for Gastric Cancer (ACTS-GC).29 It remains 
unclear whether S-1 is also effective in improving the 
prognosis of RGC. Since the prognosis of RGC is worse 
than that of PUGC, adjuvant chemotherapy might be 
necessary to improve prognosis in RGC patients. Based 
on our results, adjuvant chemotherapy should be admin-
istered to patients with BMILow advanced RGC, given 
their extremely poor prognosis. Furthermore, random-
ized control trials are required to determine effective 
adjuvant chemotherapy strategies in patients with RGC.
 This retrospective study has several limitations. One 
major limitation is the small sample size. Furthermore, 
we included patients with RGC following distal gastrec-
tomy for both benign diseases and gastric cancer, which 
might have influenced the clinical outcome. In this 
regard, it has been demonstrated that there was no sig-
nificant difference in survival between RGC where the 
initial operation was performed for benign disease and 
that where the initial operation was performed for gas-
tric cancer.15 In addition, the retrospective nature of our 
study could be considered another significant limitation, 
which may have influenced the results. Therefore, our 
findings should be confirmed by prospective studies.
 In conclusion, our retrospective study indicated that 
the prognosis of RGC was poor compared with that of 
PUGC, and that BMI is useful to predict the prognosis of 
RGC. The prognosis of patients with BMILow advanced 
RGC was extremely poor, and recurrence rates among 
this subset of patients was extremely high. Therefore, 
multidisciplinary therapy, including preoperative chemo-
therapy and intensive adjuvant chemotherapy, might be 
necessary for patients with BMILow advanced RGC.
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